Larry Gene Huffman

Title: Larry Gene Huffman: Innovator in Pharmaceutical Advancements

Introduction

Larry Gene Huffman is an accomplished inventor based in Indianapolis, Indiana, with a significant contribution to the field of pharmaceuticals. He has developed a patented formulation that holds promise for treating various cognitive disorders, showcasing his innovative spirit and dedication to improving mental health.

Latest Patents

Huffman is the inventor of a patent titled "Pyrrole and Pyrazole Derivatives as Potentiators of Glutamate Receptors." This invention pertains to specific pyrrole and pyrazole compounds and their pharmaceutically acceptable salts. The presented compounds are particularly noteworthy for their potential applications in treating schizophrenia, cognitive deficits associated with schizophrenia, Alzheimer's disease, dementia of the Alzheimer's type, mild cognitive impairment, and depression. Notably, these compounds function as potentiators on glutamate receptors, specifically targeting the AMPA and GluR family, which are critical in synaptic transmission and neural communication.

Career Highlights

Larry Gene Huffman has made significant strides in his career while working for Eli Lilly and Company, a renowned pharmaceutical company famous for its commitment to innovative drug development. His expertise in medicinal chemistry and drug design has played a vital role in his contributions to advancing pharmaceutical therapeutics.

Collaborations

In his research endeavors, Huffman collaborates with notable colleagues, including Pamela Ann Albaugh and Esteban Dominguez-Manzanares. Their collective efforts contribute to the broader goals of developing effective treatment solutions for debilitating cognitive disorders.

Conclusion

Larry Gene Huffman's innovative work in the realm of pyrrole and pyrazole derivatives sets a promising trajectory for future pharmaceutical interventions in mental health. His dedication to research and collaboration with peers places him at the forefront of efforts to develop new therapies that address critical psychiatric conditions. As the understanding of these compounds and their mechanisms evolves, they may provide significant advancements in treating complex cognitive disorders.